Symbols / APLS Stock $40.89 -0.12% Apellis Pharmaceuticals, Inc.
APLS (Stock) Chart
About
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts.
Stock Fundamentals
Scroll to Statements| Market Cap | 5.23B | Enterprise Value | 5.23B | Income | 22.39M | Sales | 1.00B | Book/sh | 2.92 | Cash/sh | 3.66 |
| Dividend Yield | — | Payout | 0.00% | Employees | 733 | IPO | — | P/E | 227.17 | Forward P/E | -167.41 |
| PEG | — | P/S | 5.21 | P/B | 13.99 | P/C | — | EV/EBITDA | 91.84 | EV/Sales | 5.21 |
| Quick Ratio | 2.59 | Current Ratio | 3.14 | Debt/Eq | 128.15 | LT Debt/Eq | — | EPS (ttm) | 0.18 | EPS next Y | -0.24 |
| EPS Growth | — | Revenue Growth | -5.90% | Earnings | 2026-05-07 | ROA | 3.53% | ROE | 7.48% | ROIC | — |
| Gross Margin | 60.34% | Oper. Margin | -25.58% | Profit Margin | 2.23% | Shs Outstand | 127.84M | Shs Float | 83.30M | Short Float | 25.78% |
| Short Ratio | 3.98 | Short Interest | — | 52W High | 40.95 | 52W Low | 16.10 | Beta | -0.20 | Avg Volume | 5.18M |
| Volume | 2.13M | Target Price | $40.93 | Recom | Hold | Prev Close | $40.94 | Price | $40.89 | Change | -0.12% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-10-16 | init | Scotiabank | — → Sector Perform | $35 |
| 2024-10-16 | init | William Blair | — → Outperform | — |
| 2024-09-24 | main | Wells Fargo | Equal-Weight → Equal-Weight | $43 |
| 2024-09-23 | main | Baird | Outperform → Outperform | $92 |
| 2024-09-20 | main | Mizuho | Neutral → Neutral | $39 |
| 2024-09-20 | reit | Needham | Buy → Buy | $85 |
| 2024-09-13 | main | JP Morgan | Overweight → Overweight | $57 |
| 2024-08-13 | main | JP Morgan | Overweight → Overweight | $64 |
| 2024-08-09 | main | UBS | Buy → Buy | $83 |
| 2024-08-09 | main | Wedbush | Neutral → Neutral | $41 |
| 2024-08-09 | main | Goldman Sachs | Buy → Buy | $74 |
| 2024-08-09 | main | Baird | Outperform → Outperform | $96 |
| 2024-08-09 | reit | Needham | Buy → Buy | $85 |
| 2024-08-02 | main | HC Wainwright & Co. | Buy → Buy | $83 |
| 2024-08-02 | main | Goldman Sachs | Buy → Buy | $66 |
| 2024-08-02 | reit | Needham | Buy → Buy | $85 |
| 2024-07-31 | main | Jefferies | Buy → Buy | $80 |
| 2024-07-26 | main | Baird | Outperform → Outperform | $86 |
| 2024-07-23 | main | Baird | Outperform → Outperform | $100 |
| 2024-07-17 | main | Goldman Sachs | Buy → Buy | $77 |
- APLS stock soars 140% today – here’s everything to know about its massive $5.6B deal with Biogen - MSN hu, 23 Apr 2026 04
- Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS - Business Wire Mon, 20 Apr 2026 19
- Apellis (NASDAQ: APLS) CFO reports bona fide stock gifts - Stock Titan Mon, 20 Apr 2026 20
- Apellis Pharmaceuticals Inc (NASDAQ:APLS) Emerges as a Growth Stock with Bullish Technical Breakout Potential - ChartMill Fri, 17 Apr 2026 12
- Apellis Pharmaceuticals (APLS) Tops Overbought Healthcare Stocks List - GuruFocus Mon, 20 Apr 2026 20
- Apellis Pharmaceuticals (APLS) Hits 2-Year High on 140% Upside from Biogen Merger - Yahoo Finance ue, 31 Mar 2026 07
- Technical Reactions to APLS Trends in Macro Strategies - Stock Traders Daily Sun, 19 Apr 2026 12
- 6-Day Rally Sends Apellis Pharmaceuticals Stock Up 140% - Trefis Wed, 08 Apr 2026 04
- APELLIS PHARMACEUTICALS ($APLS) Releases Q4 2025 Earnings - Quiver Quantitative ue, 24 Feb 2026 08
- Biogen’s $5.6B Apellis deal adds 2 approved drugs and kidney push - Stock Titan ue, 31 Mar 2026 07
- Is Apellis (APLS) stock losing momentum today (Flatline) 2026-04-20 - Social Trade Signals - Cổng thông tin điện tử tỉnh Lào Cai Mon, 20 Apr 2026 15
- Apellis Pharmaceuticals (APLS) Moves 135.4% Higher: Will This Strength Last? - Yahoo Finance Wed, 01 Apr 2026 07
- Apellis Pharmaceuticals Stock Surges 139%, With A 5-Day Winning Spree - Trefis Mon, 06 Apr 2026 07
- APLS Stock Alert: Halper Sadeh LLC is Investigating Whether Apellis Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire ue, 31 Mar 2026 07
- Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders? - Stock Titan ue, 07 Apr 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
1,003.78
+28.46%
|
781.37
+97.02%
|
396.59
+425.83%
|
75.42
|
| Operating Revenue |
|
1,003.78
+28.46%
|
781.37
+97.02%
|
396.59
+425.83%
|
75.42
|
| Cost Of Revenue |
|
102.24
-13.16%
|
117.72
+101.20%
|
58.51
+938.15%
|
5.64
|
| Reconciled Cost Of Revenue |
|
102.24
-13.16%
|
117.72
+101.20%
|
58.51
+938.15%
|
5.64
|
| Gross Profit |
|
901.55
+35.85%
|
663.64
+96.30%
|
338.08
+384.45%
|
69.79
|
| Operating Expense |
|
846.12
+2.11%
|
828.62
-3.11%
|
855.20
+28.72%
|
664.40
|
| Research And Development |
|
295.85
-9.68%
|
327.57
-7.57%
|
354.39
-8.48%
|
387.24
|
| Selling General And Administration |
|
550.26
+9.82%
|
501.05
+0.05%
|
500.81
+80.69%
|
277.16
|
| General And Administrative Expense |
|
—
|
—
|
500.81
+80.69%
|
277.16
|
| Other Gand A |
|
—
|
—
|
500.81
+80.69%
|
277.16
|
| Total Expenses |
|
948.36
+0.21%
|
946.35
+3.57%
|
913.71
+36.37%
|
670.03
|
| Operating Income |
|
55.43
+133.60%
|
-164.98
+68.10%
|
-517.12
+13.03%
|
-594.61
|
| Total Operating Income As Reported |
|
55.43
+133.60%
|
-164.98
+68.10%
|
-517.12
+13.03%
|
-594.61
|
| EBITDA |
|
70.00
+145.30%
|
-154.53
+68.79%
|
-495.13
+19.79%
|
-617.33
|
| Normalized EBITDA |
|
70.00
+145.87%
|
-152.58
+69.18%
|
-495.13
+15.28%
|
-584.43
|
| Reconciled Depreciation |
|
1.56
-13.30%
|
1.80
+0.73%
|
1.78
+14.95%
|
1.55
|
| EBIT |
|
68.44
+143.78%
|
-156.32
+68.54%
|
-496.92
+19.71%
|
-618.88
|
| Total Unusual Items |
|
0.00
+100.00%
|
-1.95
|
0.00
+100.00%
|
-32.89
|
| Total Unusual Items Excluding Goodwill |
|
0.00
+100.00%
|
-1.95
|
0.00
+100.00%
|
-32.89
|
| Special Income Charges |
|
0.00
+100.00%
|
-1.95
|
0.00
+100.00%
|
-32.89
|
| Other Special Charges |
|
—
|
1.95
|
—
|
32.89
|
| Net Income |
|
22.39
+111.31%
|
-197.88
+62.57%
|
-528.63
+18.94%
|
-652.17
|
| Pretax Income |
|
24.11
+112.26%
|
-196.72
+62.64%
|
-526.50
+19.19%
|
-651.50
|
| Net Non Operating Interest Income Expense |
|
-31.18
-12.91%
|
-27.62
-219.36%
|
-8.65
+63.53%
|
-23.71
|
| Interest Expense Non Operating |
|
44.33
+9.74%
|
40.39
+36.54%
|
29.58
-9.33%
|
32.63
|
| Net Interest Income |
|
-31.18
-12.91%
|
-27.62
-219.36%
|
-8.65
+63.53%
|
-23.71
|
| Interest Expense |
|
44.33
+9.74%
|
40.39
+36.54%
|
29.58
-9.33%
|
32.63
|
| Interest Income Non Operating |
|
13.14
+2.90%
|
12.77
-38.98%
|
20.93
+134.83%
|
8.91
|
| Interest Income |
|
13.14
+2.90%
|
12.77
-38.98%
|
20.93
+134.83%
|
8.91
|
| Other Income Expense |
|
-0.13
+96.77%
|
-4.12
-466.57%
|
-0.73
+97.81%
|
-33.18
|
| Other Non Operating Income Expenses |
|
-0.13
+93.87%
|
-2.17
-198.49%
|
-0.73
-152.43%
|
-0.29
|
| Gain On Sale Of Security |
|
—
|
—
|
—
|
—
|
| Tax Provision |
|
1.72
+48.19%
|
1.16
-45.50%
|
2.13
+218.68%
|
0.67
|
| Tax Rate For Calcs |
|
0.00
-66.19%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
+100.00%
|
-0.41
|
0.00
+100.00%
|
-6.91
|
| Net Income Including Noncontrolling Interests |
|
22.39
+111.31%
|
-197.88
+62.57%
|
-528.63
+18.94%
|
-652.17
|
| Net Income From Continuing Operation Net Minority Interest |
|
22.39
+111.31%
|
-197.88
+62.57%
|
-528.63
+18.94%
|
-652.17
|
| Net Income From Continuing And Discontinued Operation |
|
22.39
+111.31%
|
-197.88
+62.57%
|
-528.63
+18.94%
|
-652.17
|
| Net Income Continuous Operations |
|
22.39
+111.31%
|
-197.88
+62.57%
|
-528.63
+18.94%
|
-652.17
|
| Normalized Income |
|
22.39
+111.40%
|
-196.34
+62.86%
|
-528.63
+15.58%
|
-626.19
|
| Net Income Common Stockholders |
|
22.39
+111.31%
|
-197.88
+62.57%
|
-528.63
+18.94%
|
-652.17
|
| Diluted EPS |
|
0.18
+111.25%
|
-1.60
+64.04%
|
-4.45
+27.64%
|
-6.15
|
| Basic EPS |
|
0.18
+111.25%
|
-1.60
+64.04%
|
-4.45
+27.64%
|
-6.15
|
| Basic Average Shares |
|
126.14
+1.81%
|
123.91
+4.40%
|
118.68
+11.84%
|
106.11
|
| Diluted Average Shares |
|
129.85
+4.80%
|
123.91
+4.40%
|
118.68
+11.84%
|
106.11
|
| Diluted NI Availto Com Stockholders |
|
22.39
+111.31%
|
-197.88
+62.57%
|
-528.63
+18.94%
|
-652.17
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
788.73
|
| Current Assets |
|
766.33
|
| Cash Cash Equivalents And Short Term Investments |
|
351.19
|
| Cash And Cash Equivalents |
|
351.19
|
| Other Short Term Investments |
|
—
|
| Receivables |
|
224.50
|
| Accounts Receivable |
|
206.44
|
| Other Receivables |
|
18.05
|
| Taxes Receivable |
|
0.00
|
| Inventory |
|
146.36
|
| Raw Materials |
|
32.72
|
| Work In Process |
|
82.92
|
| Finished Goods |
|
30.71
|
| Prepaid Assets |
|
38.82
|
| Restricted Cash |
|
1.11
|
| Other Current Assets |
|
4.35
|
| Total Non Current Assets |
|
22.40
|
| Net PPE |
|
21.09
|
| Gross PPE |
|
21.09
|
| Other Properties |
|
21.09
|
| Other Non Current Assets |
|
1.31
|
| Total Liabilities Net Minority Interest |
|
594.21
|
| Current Liabilities |
|
247.59
|
| Payables And Accrued Expenses |
|
165.32
|
| Payables |
|
37.52
|
| Accounts Payable |
|
37.52
|
| Current Accrued Expenses |
|
127.81
|
| Current Debt And Capital Lease Obligation |
|
6.44
|
| Current Debt |
|
—
|
| Other Current Borrowings |
|
—
|
| Current Capital Lease Obligation |
|
6.44
|
| Other Current Liabilities |
|
75.83
|
| Total Non Current Liabilities Net Minority Interest |
|
346.62
|
| Long Term Debt And Capital Lease Obligation |
|
104.49
|
| Long Term Debt |
|
93.03
|
| Long Term Capital Lease Obligation |
|
11.45
|
| Other Non Current Liabilities |
|
242.13
|
| Stockholders Equity |
|
194.52
|
| Common Stock Equity |
|
194.52
|
| Capital Stock |
|
0.01
|
| Common Stock |
|
0.01
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
119.56
|
| Ordinary Shares Number |
|
119.56
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
3,035.54
|
| Retained Earnings |
|
-2,837.49
|
| Gains Losses Not Affecting Retained Earnings |
|
-3.54
|
| Other Equity Adjustments |
|
-3.54
|
| Total Equity Gross Minority Interest |
|
194.52
|
| Total Capitalization |
|
287.55
|
| Working Capital |
|
518.74
|
| Invested Capital |
|
287.55
|
| Total Debt |
|
110.93
|
| Net Debt |
|
—
|
| Capital Lease Obligations |
|
17.89
|
| Net Tangible Assets |
|
194.52
|
| Tangible Book Value |
|
194.52
|
| Current Provisions |
|
—
|
| Derivative Product Liabilities |
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
45.33
+151.59%
|
-87.87
+85.23%
|
-594.74
-15.76%
|
-513.75
|
| Cash Flow From Continuing Operating Activities |
|
45.33
+151.59%
|
-87.87
+85.23%
|
-594.74
-15.76%
|
-513.75
|
| Net Income From Continuing Operations |
|
22.39
+111.31%
|
-197.88
+62.57%
|
-528.63
+18.94%
|
-652.17
|
| Depreciation Amortization Depletion |
|
1.56
-13.30%
|
1.80
+0.73%
|
1.78
+14.95%
|
1.55
|
| Depreciation |
|
1.56
-13.30%
|
1.80
+0.73%
|
1.78
+14.95%
|
1.55
|
| Depreciation And Amortization |
|
1.56
-13.30%
|
1.80
+0.73%
|
1.78
+14.95%
|
1.55
|
| Other Non Cash Items |
|
2.50
-76.22%
|
10.49
-60.08%
|
26.29
-8.27%
|
28.66
|
| Stock Based Compensation |
|
104.00
-8.87%
|
114.13
+7.72%
|
105.94
+16.31%
|
91.08
|
| Operating Gains Losses |
|
—
|
1.95
+1524.17%
|
0.12
-99.64%
|
32.89
|
| Gain Loss On Investment Securities |
|
—
|
—
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
0.00
|
0.00
-100.00%
|
0.12
|
0.00
|
| Change In Working Capital |
|
-85.12
-363.68%
|
-18.36
+90.83%
|
-200.25
-1170.37%
|
-15.76
|
| Change In Receivables |
|
-101.28
-73.17%
|
-58.48
+70.57%
|
-198.72
-8466.95%
|
2.38
|
| Changes In Account Receivables |
|
-101.28
-73.17%
|
-58.48
+70.57%
|
-198.72
-8466.95%
|
2.38
|
| Change In Inventory |
|
-15.27
-41.95%
|
-10.76
+82.27%
|
-60.65
+12.61%
|
-69.40
|
| Change In Prepaid Assets |
|
-8.09
-125.91%
|
31.21
+152.27%
|
12.37
+207.79%
|
-11.48
|
| Change In Payables And Accrued Expense |
|
43.61
+126.65%
|
19.24
-45.21%
|
35.12
+183.75%
|
12.38
|
| Change In Accrued Expense |
|
25.39
+39.86%
|
18.15
-48.06%
|
34.95
+653.71%
|
-6.31
|
| Change In Payable |
|
18.22
+1573.37%
|
1.09
+540.59%
|
0.17
-99.09%
|
18.69
|
| Change In Account Payable |
|
18.22
+1573.37%
|
1.09
+540.59%
|
0.17
-99.09%
|
18.69
|
| Change In Other Working Capital |
|
-0.03
+87.73%
|
-0.28
-246.25%
|
-0.08
-23.08%
|
-0.07
|
| Change In Other Current Assets |
|
-4.06
-676.03%
|
0.70
-93.97%
|
11.70
-76.80%
|
50.43
|
| Change In Other Current Liabilities |
|
—
|
—
|
—
|
—
|
| Investing Cash Flow |
|
-0.31
+22.33%
|
-0.40
+40.21%
|
-0.67
-101.13%
|
59.89
|
| Cash Flow From Continuing Investing Activities |
|
-0.31
+22.33%
|
-0.40
+40.21%
|
-0.67
-101.13%
|
59.89
|
| Net PPE Purchase And Sale |
|
-0.31
+22.33%
|
-0.40
+40.21%
|
-0.67
+55.77%
|
-1.52
|
| Purchase Of PPE |
|
-0.31
+22.33%
|
-0.40
+47.87%
|
-0.77
+49.28%
|
-1.52
|
| Sale Of PPE |
|
0.00
|
0.00
-100.00%
|
0.10
|
0.00
|
| Capital Expenditure |
|
-0.31
+22.33%
|
-0.40
+47.87%
|
-0.77
+49.28%
|
-1.52
|
| Net Investment Purchase And Sale |
|
—
|
0.00
|
0.00
-100.00%
|
61.42
|
| Purchase Of Investment |
|
—
|
0.00
|
0.00
+100.00%
|
-331.86
|
| Sale Of Investment |
|
—
|
0.00
|
0.00
-100.00%
|
393.28
|
| Financing Cash Flow |
|
8.88
-94.05%
|
149.24
-62.17%
|
394.50
+7.89%
|
365.66
|
| Cash Flow From Continuing Financing Activities |
|
8.88
-94.05%
|
149.24
-62.17%
|
394.50
+7.89%
|
365.66
|
| Net Issuance Payments Of Debt |
|
0.00
-100.00%
|
365.45
|
0.00
|
0.00
|
| Issuance Of Debt |
|
0.00
-100.00%
|
365.45
|
0.00
|
0.00
|
| Repayment Of Debt |
|
—
|
—
|
—
|
—
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
365.45
|
0.00
|
0.00
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
—
|
| Net Long Term Debt Issuance |
|
0.00
-100.00%
|
365.45
|
0.00
|
0.00
|
| Net Common Stock Issuance |
|
0.00
|
0.00
-100.00%
|
384.39
+1.12%
|
380.12
|
| Proceeds From Stock Option Exercised |
|
8.89
-52.76%
|
18.83
-75.44%
|
76.65
+198.01%
|
25.72
|
| Net Other Financing Charges |
|
-0.01
+100.00%
|
-235.04
-253.23%
|
-66.54
-65.60%
|
-40.18
|
| Changes In Cash |
|
53.90
-11.60%
|
60.97
+130.35%
|
-200.91
-127.81%
|
-88.19
|
| Effect Of Exchange Rate Changes |
|
1.25
+289.68%
|
-0.66
-588.15%
|
0.14
+127.66%
|
-0.49
|
| Beginning Cash Position |
|
412.61
+17.12%
|
352.30
-36.30%
|
553.07
-13.82%
|
641.75
|
| End Cash Position |
|
467.76
+13.37%
|
412.61
+17.12%
|
352.30
-36.30%
|
553.07
|
| Free Cash Flow |
|
45.01
+151.00%
|
-88.27
+85.18%
|
-595.51
-15.57%
|
-515.27
|
| Interest Paid Supplemental Data |
|
41.23
+40.40%
|
29.37
+793.73%
|
3.29
-34.32%
|
5.00
|
| Income Tax Paid Supplemental Data |
|
—
|
1.65
|
0.00
-100.00%
|
4.92
|
| Common Stock Issuance |
|
0.00
|
0.00
-100.00%
|
384.39
+1.12%
|
380.12
|
| Issuance Of Capital Stock |
|
0.00
|
0.00
-100.00%
|
384.39
+1.12%
|
380.12
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-20 View
- 42026-04-08 View
- 8-K2026-03-31 View
- 42026-03-13 View
- 42026-03-03 View
- 8-K2026-03-02 View
- 10-K2026-02-24 View
- 42026-02-13 View
- 42026-02-05 View
- 42026-01-30 View
- 42026-01-30 View
- 42026-01-30 View
- 42026-01-30 View
- 42026-01-30 View
- 42026-01-30 View
- 42026-01-30 View
- 42026-01-30 View
- 42026-01-30 View
- 42026-01-23 View
- 42026-01-23 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|